Ozanimod Treatment Results in Higher Rates of No Evidence of Disease Activity vs Interferon ß-1a

NeurologyLiveJune 2022
Volume 5
Issue 3

After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.

Ludwig Kappos, MD

Ludwig Kappos, MD

In a post hoc analysis of the phase 3 RADIANCE trial (NCT02047734) and its open-label extension DAYBREAK (NCT02576717), a higher proportion of patients with relapsing multiple sclerosis (MS) achieved no evidence of disease activity status 3 or 4 (NEDA-3 and NEDA-4) following treatment with oral ozanimod (Zeposia; Bristol Myers Squibb) vs intramuscular interferon ß-1a (IFN).1

At months 12 and 24 of RADIANCE, investigators observed NEDA-3 rates of 31.2% and 24.6% (P <.05) for ozanimod-treated patients vs 26.9% and 17.0% for those on IFN, respectively. In DAYBREAK, rates were 16.2% (P <.05), 13.4% (P <.05), and 10.7% with continuous ozanimod at months 12, 24, and 36, respectively, compared with rates of 9.8%, 8.6%, and 7.4% for those on/transitioned from IFN.

These findings were presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, Washington, by lead investigator Ludwig Kappos, MD, professor of neurology, University Hospital Basel, Switzerland. “We see the effects in the first year were repeated over time, and that a significant number of patients remained disease activity free under these quite strict criteria,” he told NeurologyLive®. "Those who had evidence of disease activity mainly had this through MRIs, so through lesions that occurred in their regularly repeated and standardized assessments."

Ozanimod, a sphingosine-1 phosphate (S1P) receptor, has been FDA-approved to treat relapsing forms of MS since March 2020. In this analysis, NEDA-3 was defined as no new gadolinium-enhancing lesions, no new/enlarging T2 lesions, no relapses, and no progression on Expanded Disability Status Scale (EDSS) scores from baseline. Achieving NEDA-4 required NEDA-3 status plus annualized whole brain volume loss of less than 0.4%.

For those on continuous ozanimod, 21.5% and 14.0% (P <.05) of patients achieved NEDA-4 in RADIANCE at months 12 and 24, respectively, compared with rates of 16.3% and 7.8% for those on IFN. The therapeutic effect continued to show greater results than IFN in DAYBREAK, with NEDA-4 rates of 10.0%, 10.4%, and 10.3% in months 12, 24, and 36 vs rates of 5.9%, 6.2%, and 6.3% for those on/transitioned from IFN, respectively.

Rebaselining to month 12 resulted in greater rates of achieving NEDA-3 and NEDA-4 for patients on continuous ozanimod vs those who transitioned from IFN. After rebaselining, NEDA-3 rate at RADIANCE month 24 was 52.6% (P <.05), and DAYBREAK months 12, 24, and 36, rates were 33.1% (P <.05), 26.3% (P <.05), and 21.3% in ozanimod-treated patients, respectively. In those same trials, those NEDA-3 rates were 33.4%, 20.5%, 17.4%, and 14.8% for those on/transitioned from IFN. Rebaselined rates of NEDA-4 were 33.5% (P <.05), 20.0% (P <.05), 16.7%, and 14.1% for continuous ozanimod and 19.7%, 11.7%, 11.2%, and 11.0% for those on/transitioned from IFN, respectively.

RADIANCE was a multicenter, double-blind, double-dummy study that randomized patients with MS in a 1:1:1 fashion to either daily ozanimod 1.0 mg or 0.5 mg or weekly intramuscular IFN 30 μg, with annualized relapse rate (ARR) as the primary end point. After 24-months of treatment, adjusted ARRs were 0.17 (95% CI, 0.14-0.21) for ozanimod 1.0 mg, 0.22 (95% CI, 0.18-0.26) with ozanimod 0.5 mg, and 0.28 (95% CI, 0.23-0.32) for IFN, with rate ratios vs IFN of 0.62 (95% CI, 0.51-0.77; P <.0001) and 0.79 (95% CI, 0.65-0.96; P = .0167) for the ozanimod 1.0 mg and 0.5 mg groups, respectively.2

Click here for more coverage of AAN 2022.

1. Kappos L, Comi G, Selmaj K, et al. Evaluating no evidence of disease activity in patients with relapsing multiple sclerosis: post hoc analysis of the phase 3 RADIANCE and open-label extension studies of ozanimod. Presented at: 2022 AAN Annual Meeting; April 2-7; Seattle, Washington. Abstract 0839
2. Cohen JA, Comi G, Selmaj K, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial. Lancet Neuro. 2019;18(11):1021-1033.
Related Videos
Sanjay R. Patel, MD, MS
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.